Advertisement
Advertisement

RVMD

RVMD logo

Revolution Medicines, Inc. Common Stock

96.87
USD
Sponsored
-1.33
-1.35%
Jan 30, 16:00 UTC -5
Closed
exchange

After-Market

96.91

+0.04
+0.04%

RVMD Earnings Reports

Positive Surprise Ratio

RVMD beat 7 of 24 last estimates.

29%

Next Report

Date of Next Report
Feb 24, 2026
Estimate for Q4 25 (Revenue/ EPS)
$3.97M
/
-$1.61
Implied change from Q3 25 (Revenue/ EPS)
--
/
--
Implied change from Q4 24 (Revenue/ EPS)
--
/
+43.75%

Revolution Medicines, Inc. Common Stock earnings per share and revenue

On Nov 05, 2025, RVMD reported earnings of -1.61 USD per share (EPS) for Q3 25, missing the estimate of -1.44 USD, resulting in a -11.24% surprise. Revenue reached --, compared to an expected 1.61 million, with a -100.00% difference. The market reacted with a +3.44% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 20 analysts forecast an EPS of -1.61 USD, with revenue projected to reach 3.97 million USD, implying an increase of 0.00% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
FAQ
For Q3 2025, Revolution Medicines, Inc. Common Stock reported EPS of -$1.61, missing estimates by -11.24%, and revenue of $0.00, -100% below expectations.
The stock price moved up 3.44%, changed from $59.34 before the earnings release to $61.38 the day after.
The next earning report is scheduled for Feb 24, 2026.
Based on 20 analysts, Revolution Medicines, Inc. Common Stock is expected to report EPS of -$1.61 and revenue of $3.97M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement